Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
Get this delivered to your inbox, and more info about our products and services.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Nuovo farmaco dimagrante di Novo Nordisk batte la ritirata, Eli Lilly avanza
